Genasense: Phase I/II data; Phase III

Of 22 evaluable patients with hormone refractory prostate cancer in a 26-patient dose escalation Phase I trial of Genasense in combination with Immunex Corp.’s Novantrone mitoxantrone, 8 patients ha...